OMB-No. 0651-0011 INFORMATION DISCLOSURE CITATION Atty. Docket No. Serial No. 09/809,329 Marie-Christine BISSERY March 16, 2001 Group: 1614

FOREIGN PATENT DOCUMENTS								
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No		
M-C.H	EP 0 056 692 B1	07/28/82	EPO					
·	EP 0 088 642 A2	09/14/83	ЕРО					
	EP 0 296 612 B1	12/28/88	ЕРО					
	EP 0 321 122 B1	06/21/89	ЕРО			-		
	EP 0 325 247 B1	07/26/89	ЕРО					
	EP 0 540 099 B1	05/05/93	ЕРО					
	EP 0 737 686 B1	10/16/96	ЕРО					
	WO 96/37496	11/28/96	PCT					
	WO 96/38146	12/05/96	PCT					
MCH	WO 96/38449	12/05/96	PCT					

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
M·c·H	T.H. Corbett et al., "Evaluation of Single Agents and Combinations of Chemotherapeutic Agents in Mous Colon Carcinomas," <i>Cancer</i> , 40 (5):2660-2680 (1977).						
	T.H. Corbett et al., "Response of Transplantable Tumors of Mice to Anthracenedione Derivatives Alone and in Combination with Clinically Useful Agents," Cancer Treatment Reports, 66(5):1187-1200 (May 1982).						
	David L. Emerson et al., "In vivo Antitumor Activity of Two New Seven-substituted Water-soluble Camptothecin Analogues," Cancer Research, 55:603-609 (February 1995).						
	Isabelle Madelaine et al., "Sequential Modifications of Topoisomerase I Activity in a Camptothecin-Resistant Cell Line Established by Progressive Adaptation," <i>Biochemical Pharmacology</i> , 45 (2):339-348 (1993).						
M-C·H	T. Saotome et al., "Combination Chemotherapy with Irinotecan and Adriamycin for Refractory or Relapsed Malignant Lymphoma (ML): A Pilot Study," Abstract 540P, Ann. Oncol., 7(Suppl. 5): 113 (1996).						

Examiner /	lichae	-C. Henry	Date Considered 8/8/02		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					
Form PTO 1449			Patent and Trademark Office - U.S. Department of Commerce		

Applicant

Filing Date

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	03806.0493-00000	Serial No.	09/809,329	. 3 . 3
Applicant	Marie-Christine BISSERY			1 2 160
Filing Date	March 16, 2001	Group:	1614	0/2

FOREIGN PATENT DOCUMENTS								
OIPE SCIES	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No		
JUL 27 TUM E								
& TRADEMINE								
& TRADEM								
						100.0		
						<u></u>		

Demonstrated or Potential Clinical Utility for Treatment of Advanced Solid Tu Cancer Research - Cancer Drug Development (Part B), Vol. XVII, pp. 3-51 (1	
P. Vrignaud et al., "In vivo Chemosensitivity of a P388 Murine Leukemia Resistable Abstract 2160, Proc. Amer. Soc. Cancer Res., 35:363 (March 1994).	stant to Camptothecin,"
·	

Examiner M	chael	. (Henri	1	Date Considered	81	18/	102
*Examiner:	Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
Form PTO 1449				,	Patent and Tra	demark	Offic	ce - U.S. Department of Commerce

÷ >+ (SEP 10 2000 SEP 10	SCLOSURE	CITATION	OMB No. CENT	51 ,00 11 EP 1	RECE
Atty. Docket No.	3806.0493	Serial No.	09/809,329	ER -	မ	豐
Applicant	Marie-Christine BISSERY			600/	001	M
Filing Date	March 16, 2001	Group:	1614	2900		U

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
M·C·H	4,473,692	09/25/84	Miyasaka et al.			
M·C·H	4,545,880	10/08/85	Miyasaka et al.			
M-C+H	6,191,119 B1	02/20/01	Rubinfeld			
				ļ		

FOREIGN PATENT DOCUMENTS							
_	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No	
M·C·H	EP 0 074256 B1	03/16/83	EPO				
M-c.H	WO 90/03169	04/05/90	PCT			-	
Met	WO 97/00876	01/09/97	PCT			No	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
1						

Examiner N	ichael - C. Henr	1 Date Considered	8/	8	02	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						
Form PTO 1449		Patent and Tra	demark	Offic	e - U.S. Department of Commerce	

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

SEP 1 0 2001 Atty. Docket 00000 Serial No. 09/809,329 e-Christine BISSERY Applicant Filing Date March 16, 2001 1614 Group

	DOCUMENTS

-"	Document Number	Date	Country	Class	Sub Class	Translation Yes or No
M-C·H	JP 57-116015	07/19/82	Japan			
1	JP 57-116074	07/19/82	Japan			
	JP 59-5188	01/12/84	Japan			
	JP 59-51289	03/24/84	Japan			
	JP 60-19790	01/31/85	Japan			
	JP 1-246287	10/02/89	Japan	-		
MCIT	JP 1-249777	10/05/89	Japan			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

M-C·H	Abstract: Japio No. 00965715 for JP 57-116015.
	Abstract: Japio No. 00965774 for JP 57-116074.
	Abstract: Japio No. 01293588 for JP 59-5188.
	Abstract: Japio No. 01541290 for JP 60-19790.
	Abstract: Japio No. 02948687 for JP 1-246287.
	Abstract: Japio No. 02952177 for JP 1-249777.
	Abstract: Derwent No. 01984-110813/198418 for JP 59-51289.
	Tomio Furuta and Teruo Yokokura, "Combination Therapy of CPT-11, a Camptothecin Derivative, with Various Antitumor Drugs Against L1210 Leukemia," <i>Japanese Journal of Cancer and Chemotherapy</i> , 18 (3):393-402 (March 1991); English Abstract p. 402.
	M. Ise, C. Sakai, H. Tsujimura, K. Kumagai, T. Takenouchi and T. Takagi, "Sucessful Treatment with CPT-11 and Adriamycin for Hemophagocytic Syndrome Associated with Intravascular Lymphomatosis," <i>Jpn J. Clin. Hematology</i> , 39(11):1131-1136; English Abstract p. 1136.
M·C·H	C. Sakai, T. Saotome, A. Takeshita, C. Nakaseko, K. Kumagai, and T. Takagi, "Irinotecan + Adriamycin OOL." <i>Jpn. J. Cancer Chemotherapy</i> 26(5):709-714 (1999): Chemical Abstract 115:21789.

Examiner Date Considered 18

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation *Examiner:

if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 Patent and Trademark Office - U.S. Department of Commerce